Skip to main content
. 2015 Aug;56(8):823–830.

Figure 1.

Figure 1

Mild darkening of the skin and enlargement of the subcutaneous area at the injection site (white arrows) after second administration of subcutaneous paclitaxel in a mixed breed dog (A) and boxer (B). “Target” skin lesion at the injection site of paclitaxel (black arrow) in a boxer (B).